Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD
Sponsor: Eisai Inc.
Listed as NCT00304421, this PHASE4 trial focuses on Gastroesophageal Reflux Disease and remains completed. Sponsored by Eisai Inc., it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
- PriCara, Unit of Ortho-McNeil, Inc.
- VA Greater Los Angeles Healthcare System
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Los Angeles, United States